Green tea polyphenols, epicatechin gallate and epigallocatechin gallate, alleviated aberrant metabolic changes caused by olanzapine in rats

سال انتشار: 1404
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 5

فایل این مقاله در 13 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_AJP-15-5_010

تاریخ نمایه سازی: 27 مرداد 1404

چکیده مقاله:

Objective: Olanzapine, a well-known antipsychotic drug, causes considerable weight gain and metabolic abnormalities in patients. Green tea (Camellia sinensis) has anti-obesity, antihypertensive, antihyperlipidemic, and anti-diabetes effects. The aim of this study was to investigate the potential effects of epicatechin gallate (ECG) and epigallocatechin gallate (EGCG) as green tea polyphenols on metabolic changes induced by olanzapine.Materials and Methods: We used fourteen groups of rats and subjected them to intraperitoneal injections once a day for eleven days: ۱: Control. ۲: Olanzapine (۵ mg/kg/day). ۳, ۴, and ۵: Olanzapine + EGCG (۱۰, ۲۰, and ۴۰ mg/kg/day, respectively). ۶, ۷, and ۸: EGCG (۱۰, ۲۰, and ۴۰ mg/kg/day, respectively). ۹, ۱۰, and ۱۱: Olanzapine + ECG (۱۰, ۲۰, and ۴۰ mg/kg/day, respectively). ۱۲, ۱۳, and ۱۴: ECG (۱۰, ۲۰, and ۴۰ mg/kg/day). The body weights were recorded every three days and food consumption was evaluated every day. At the end of the study, lipid profile, systolic blood pressure (SBP), leptin and fasting blood sugar (FBS) levels, and locomotor activity were assessed.Results: Olanzapine considerably increased weight, food intake, triglycerides, low-density lipoprotein (LDL), cholesterol, SBP, leptin, and FBS, and decreased high-density lipoprotein (HDL), and locomotor activity. Co-administration of ECG or EGCG at different doses significantly suppressed olanzapine-induced weight gain, and elevated plasma lipids, SBP, leptin, and FBS levels. Both compounds also considerably increased locomotor activity and HDL levels.Conclusion: These findings suggest that ECG and EGCG could be promising adjunct therapies to counteract the metabolic side effects of olanzapine.

نویسندگان

Elmira Hoseini

Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Mohaddeseh Sadat Alavi

Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Roohbakhsh

Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran